



**FROM
DYSLIPIDEMIA
CONTROL TO
CARDIOVASCULAR
SAFETY**

In Dyslipidemia with High TG

^{Rx} Diet, Exercise &

Roswow™-F $\frac{10}{20}$

Rosuvastatin 10/20 mg + Fenofibrate 160 mg Tablets



In Dyslipidemia with High TG

R_x Diet, Exercise &

Rosw[™]w-F^{10/20}

Rosuvastatin 10/20 mg + Fenofibrate 160 mg Tablets

Background

- Statin therapy effectively reduces LDL-C, yet residual cardiovascular risk persists due to elevated triglycerides and low HDL-C. Current guidelines recommend diet, exercise, and combination therapy. Rosuvastatin + Fenofibrate provides comprehensive lipid management with established efficacy and safety.

Indication

- **ROSWOW-F**, with diet and exercise, is indicated in adults with dyslipidemia and elevated triglycerides (High TG) to:
 - Reduce LDL-C, Total Cholesterol, Triglycerides
 - Increase HDL-C

Product Description

- **ROSWOW-F (10/ 20)** Fixed-dose combination of Rosuvastatin + Fenofibrate, offers dual control of cholesterol and triglycerides, with added HDL-C improvement.

Mechanism of Action

- **Rosuvastatin**: Acts by competitively inhibiting the enzyme HMG-CoA reductase, the rate limiting step in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, thereby upregulating LDL receptors and enhancing clearance of LDL-C from circulation.
- **Fenofibrate** exerts its effects by activating peroxisome proliferator-activated receptor alpha (PPAR-α), which enhances lipolysis and promotes the clearance of triglyceride-rich lipoproteins through activation of lipoprotein lipase and reduction of apolipoprotein C-III production. This decrease in triglycerides leads to a shift in LDL particle size from small, dense particles to larger, more buoyant particles. These larger LDL particles have higher affinity for hepatic cholesterol receptors, allowing faster catabolism and improved lipid profile.

Dosage :

- The recommended daily dose of **ROSWOW-F** is one tablet a day or as prescribed by the doctor.

References:

1. Ann Pharmacother. 2002 Nov;36(11):1749-58.
2. Clin. Lipidol. (2010) 5(3), 627-649



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place,
New Delhi - 110019 Tel.: 011-47589500-51 (50 lines)
Web: www.medicamen.com/lifesciences
E-mail: info@medicamenlifesciences.com

I am:
Call me on:
Mail me at:

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd